Advertisement


Martin H. Dreyling, MD, PhD, on Follicular Lymphoma: Safety and Efficacy of Tisagenlecleucel

EHA 2021 Virtual Congress

Advertisement

Martin H. Dreyling, MD, PhD, of University Hospital Munich Grosshadern Klinikum, discusses phase II results from the ELARA trial, which suggests tisagenlecleucel may be a promising immunotherapy for adults with relapsed or refractory follicular lymphoma (Abstract S210).



Related Videos

Hematologic Malignancies
Immunotherapy

Efstathios Kastritis, MD, on Amyloidosis: Standard of Care Plus Daratumumab

Efstathios Kastritis, MD, of the University of Athens, discusses updated phase III results from the ANDROMEDA study of patients with newly diagnosed light chain amyloidosis. The trial further supports the use of daratumumab plus VCd (bortezomib, cyclophosphamide, and dexamethasone), which was shown to be clinically superior to VCd alone (Abstract S189).

Lymphoma

Gaurav Goyal, MD, on DLBCL: Comparing R-CHOP and R-EPOCH for Overall Survival Benefits

Gaurav Goyal, MD, of the University of Alabama at Birmingham, reports on findings from a large multi-institutional database study, which showed there was no apparent difference in overall survival between R-CHOP and R-EPOCH among patients with advanced-stage MYC-rearranged, double-hit, or triple-hit diffuse large B-cell lymphoma. Further studies are needed for better risk stratification to optimize outcomes (Abstract S224).

Multiple Myeloma

Cristina Gasparetto, MD, on Multiple Myeloma: Selinexor, Carfilzomib, and Dexamethasone in Carfilzomib-Nonrefractory Patients

Cristina Gasparetto, MD, of Duke University, discusses findings from a study that suggests patients with heavily pretreated multiple myeloma benefit from weekly selinexor, carfilzomib, and dexamethasone, which was reported to be active, with an overall response rate of 78% and an overall progression-free survival of 23 months (Abstract S188).

Multiple Myeloma
Immunotherapy

Philippe Moreau, MD, on Newly Diagnosed Multiple Myeloma: Daratumumab Maintenance vs Observation

Philippe Moreau, MD, of University Hospital Hôtel-Dieu, discusses findings from the CASSIOPEIA trial, Part 1, on daratumumab maintenance vs observation in patients with newly diagnosed multiple myeloma who have been treated with bortezomib, thalidomide, and dexamethasone, with or without daratumumab, and autologous stem cell transplantation (Abstract S180).

Leukemia

Keith W. Pratz, MD, on AML: Venetoclax, Azacitidine, and Disease Response

Keith W. Pratz, MD, of the University of Pennsylvania, discusses the outcomes of patients with acute myeloid leukemia who took part in the VIALE-A trial and were treated with venetoclax and azacitidine. The patients had achieved both composite complete remission and measurable residual disease of < 10-3 (Abstract S137).

Advertisement

Advertisement



Advertisement